tiprankstipranks
Trending News
More News >
Hogy Medical Co (JP:3593)
:3593

Hogy Medical Co (3593) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Hogy Medical Co

(OTC:3593)

Rating:63Neutral
Price Target:
Hogy Medical Co presents a mixed outlook. Financial performance is strong due to low leverage and consistent cash flow. However, technical analysis shows bearish signs with downward momentum. Valuation is a concern with a high P/E ratio, though the dividend yield provides some support.

Hogy Medical Co (3593) vs. iShares MSCI Japan ETF (EWJ)

Hogy Medical Co Business Overview & Revenue Model

Company DescriptionHogy Medical Co.,Ltd., together with its subsidiaries, manufactures and sells medical supplies to healthcare facilities in Japan. It offers kit products for surgery applications; all-in-one kits for pre/mid/post-surgery; non-woven products, including gowns, personal protective equipment and wearables, drapes, packaged products, instrument table covers, and wraps; and Tigalyer, a multi-layer fabric. The company also provides sterilization products, such as hybrid Mekkin bags, hybrid Mekkin bags ID layered type, and autoclave forceps stand caps; Mekkin cards, which are detection cards used to judge the sterilization process when sterilizing in an autoclave; ethylene oxide gas cards that are detection cards used to judge the sterilization process when sterilizing using ethylene oxide gas; and indicator tapes for autoclave sterilization. In addition, it offers ME equipment operation management system; narcotics/poisons box, an automatic drug reading management system using radio frequency identification; and Securea, a polyurethane sponge for endoscopic surgery. The company was formerly known as Hogy Co., Ltd. and changed its name to Hogy Medical Co.,Ltd. in 1987. Hogy Medical Co.,Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyHogy Medical Co makes money by manufacturing and selling medical supplies and equipment to hospitals, clinics, and other healthcare facilities. The company's revenue model is primarily based on the sale of disposable medical products, which are essential for maintaining hygiene and safety standards in medical environments. Key revenue streams include direct sales of surgical kits and disposable medical clothing, as well as long-term supply contracts with healthcare institutions. Hogy Medical Co might also engage in partnerships with medical distributors to expand its market reach. The company's financial performance is influenced by factors such as healthcare industry demand, regulatory changes, and advancements in medical technology.

Hogy Medical Co Financial Statement Overview

Summary
Hogy Medical Co demonstrates financial stability with a strong balance sheet and consistent cash flow generation. Despite some decline in profitability margins, the company maintains solid revenue and gross margin performance. The low leverage and high equity ratio contribute to financial resilience.
Income Statement
75
Positive
Hogy Medical Co shows solid revenue stability with a slight increase in revenue over the years. The Gross Profit Margin is consistently strong, indicating effective cost management. However, there's a notable decline in Net Profit Margin and EBIT Margin in the latest year compared to prior periods, suggesting increased operational costs or lower pricing power. The EBITDA Margin remains robust, highlighting strong earnings before accounting for interest, taxes, depreciation, and amortization.
Balance Sheet
82
Very Positive
The company maintains a healthy balance sheet with a very low Debt-to-Equity Ratio, indicating low financial leverage. The Return on Equity has seen some fluctuation but remains positive, reflecting efficient use of equity capital. The Equity Ratio is high, signifying strong financing through equity and low reliance on debt, which provides financial stability.
Cash Flow
78
Positive
Hogy Medical Co exhibits strong cash flow with consistent Free Cash Flow generation and growth in Operating Cash Flow. The Free Cash Flow to Net Income Ratio indicates solid cash generation relative to net income, despite some variability in Free Cash Flow growth over the years. The Operating Cash Flow to Net Income Ratio showcases the company's ability to convert net income into cash effectively.
Breakdown
Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income StatementTotal Revenue
39.14B39.10B38.98B36.78B36.50B
Gross Profit
12.62B12.49B15.74B15.42B15.33B
EBIT
3.46B4.17B6.63B6.13B5.63B
EBITDA
8.75B10.71B10.25B10.25B10.18B
Net Income Common Stockholders
1.52B2.80B4.32B4.37B4.96B
Balance SheetCash, Cash Equivalents and Short-Term Investments
22.00B19.42B18.86B14.36B20.55B
Total Assets
97.89B100.04B102.18B98.97B105.64B
Total Debt
13.67B5.82B8.89B10.00B330.00M
Net Debt
-8.34B-13.60B-9.97B-4.36B-20.22B
Total Liabilities
23.56B13.92B18.50B18.97B9.69B
Stockholders Equity
74.32B86.11B83.61B79.96B95.88B
Cash FlowFree Cash Flow
6.53B4.32B7.78B5.30B-686.00M
Operating Cash Flow
11.76B7.12B9.18B8.50B6.85B
Investing Cash Flow
-4.12B-3.26B-1.95B-3.81B-6.95B
Financing Cash Flow
-5.46B-3.89B-3.14B-11.05B-2.50B

Hogy Medical Co Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3910.00
Price Trends
50DMA
4128.40
Negative
100DMA
4475.10
Negative
200DMA
4518.69
Negative
Market Momentum
MACD
-91.52
Negative
RSI
44.95
Neutral
STOCH
57.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3593, the sentiment is Negative. The current price of 3910 is below the 20-day moving average (MA) of 3914.00, below the 50-day MA of 4128.40, and below the 200-day MA of 4518.69, indicating a bearish trend. The MACD of -91.52 indicates Negative momentum. The RSI at 44.95 is Neutral, neither overbought nor oversold. The STOCH value of 57.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3593.

Hogy Medical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
¥55.17B57.541.87%1.94%0.10%-41.21%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
DE6SN
€981.87M28.574.78%2.74%
$966.58M17.106.55%3.60%
76
Outperform
¥118.12B19.57
3.25%11.54%-8.30%
72
Outperform
¥21.64B16.03
2.16%14.12%56.92%
53
Neutral
¥10.31B116.15
4.03%6.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3593
Hogy Medical Co
3,910.00
152.09
4.05%
DE:6SN
Nakanishi
11.60
-1.91
-14.14%
PBHDF
Paramount Bed Holdings Co
17.85
0.02
0.11%
JP:3154
Medius Holdings Co., Ltd.
974.00
34.87
3.71%
JP:7702
JMS Co., Ltd.
424.00
-88.11
-17.21%
JP:7730
Mani, Inc.
1,191.00
-685.87
-36.54%

Hogy Medical Co Corporate Events

Hogy Medical’s Board Opposes Shareholder Proposal on Director Elections
May 14, 2025

Hogy Medical Co., Ltd.’s Board of Directors has decided to oppose a shareholder proposal from Nippon Active Value Fund plc regarding the election of three directors at the upcoming Annual General Meeting. The Board believes that its current composition, which includes a Nomination Committee to ensure independence and accountability, is optimal for implementing its medium-term management plan aimed at sustainable growth and enhanced corporate governance.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Co. Announces Leadership Changes to Strengthen Management
May 14, 2025

Hogy Medical Co., Ltd. announced a significant change in its leadership structure, with Taisuke Fujita being appointed as the new Representative Director and Vice President, effective June 20, 2025. This strategic move aims to strengthen the company’s management framework, potentially impacting its operational efficiency and market positioning. Additionally, the company will see the resignation of two outside directors, Kiyoshi Uesugi and Yuta Kinose, on the same date.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Co. Reports Decline in Profits Despite Stable Sales
Apr 24, 2025

Hogy Medical Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a slight increase in net sales by 0.1% to ¥39,138 million. However, the company experienced a significant decline in profits, with operating profit down by 8.6% and profit attributable to owners of the parent down by 45.8%. Despite these challenges, the company maintained its dividend payments and forecasts a recovery in profits for the next fiscal year, indicating a strategic focus on improving financial performance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.